35 / 43
CheckMate 025: monotherapy
0
6
12
18
24
30
52%
42%
OS rates
39%
30%
36
42
48
54
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
410
359
305 252
205
175
151
109
31
0
411
325
268 214
163
133 110
85
32
1
Median OS, Months
(95% CI)
Nivolumab
25.8 (22.2–29.8)
Everolimus
19.7 (17.6–22.1)
HR, 0.74 (95.45% CI, 0.63–0.88)
P
=0.0005
No. of patients at risk
Nivolumab
Everolimus
Overall Survival (Probability)
Months
Minimum follow-up: ~38 months.
Reported as of June 2017.
CI, confidence interval; HR, hazard ratio; OS, overall survival.
Included with permission from Sharma P et al. Poster presentation at KCS 2017.
OS: 3-Year Follow-up